Welcome to our dedicated page for Tevogen Bio news (Ticker: TVGNW), a resource for investors and traders seeking the latest updates and insights on Tevogen Bio stock.
Tevogen Bio Holdings Inc. (TVGNW) is a clinical-stage biotechnology company pioneering AI-driven precision T cell therapies for infectious diseases, cancers, and neurological disorders. This page serves as the definitive source for official company announcements, research breakthroughs, and strategic developments.
Investors and industry observers will find timely updates on clinical trial progress, regulatory milestones, and partnership announcements. Our curated collection includes press releases covering therapeutic advancements, financial results, intellectual property updates, and leadership changes.
Key focus areas include Tevogen's innovative use of CD8+ cytotoxic T lymphocytes, developments in its Tevogen.AI platform, and strategic collaborations enhancing its immunotherapy pipeline. The news archive provides chronological tracking of the company's progress in creating accessible off-the-shelf treatments.
Bookmark this page for direct access to verified information about TVGNW's scientific advancements and corporate updates. Check regularly for new developments in precision immunotherapy and AI-enhanced drug discovery.
Tevogen Bio, a clinical-stage specialty immunotherapy company, hosted its first post-public listing social engagement on May 31, 2024. The event, attended by patients, first responders, elected officials, and U.S. Congress members, highlighted the company's efforts in developing CD8+ cytotoxic T cell therapies for infectious diseases, cancers, and neurological disorders. Key attendees included several New Jersey mayors, U.S. Congressmen Josh Gottheimer and Robert Menendez, and first responder representatives. The discussion focused on understanding patient needs and exploring how Tevogen's model could reduce healthcare costs and improve outcomes.
Tevogen Bio has announced that its investigational immunotherapy, TVGN 489, remains effective against FLiRT strains of SARS-CoV-2, the dominant COVID-19 variants. TVGN 489, a Cytotoxic CD8+ T lymphocyte treatment, targets multiple conserved peptides across SARS-CoV-2 proteins, maintaining efficacy despite mutations. A phase I trial showed significant clinical improvement in high-risk patients, with virus reduction over 99% within 14 days and no significant adverse events. Tevogen plans further trials to assess TVGN 489's ongoing efficacy.
Tevogen Bio has reported its Q1 2024 financial results, indicating significant strides in its financial management and operations. The company eliminated $94.9 million in liabilities by converting promissory notes into common stock, resulting in a net income of $11.3 million. Operating cash usage was $2.1 million for the quarter. A new line of credit for up to $36 million has been secured, with an option for an additional $14 million contingent on stock price performance. Non-cash expenses were substantial, primarily driven by $25.2 million in stock-based compensation. Tevogen also incurred a one-time transaction cost of $7.5 million related to its recent business combination. The company remains committed to innovative product development and has made notable progress, including a successful proof-of-concept clinical trial for its T cell platform targeting Long COVID patients.
Tevogen Bio Holdings, a clinical-stage biotech company specializing in immunotherapy, has appointed William Keane as the Vice President of Strategic Initiatives. Keane, a former Chief of Police in Warren, NJ, and a graduate of the FBI National Academy, brings 35 years of leadership experience to the role. He will ensure compliance with regulatory guidelines and assist in procuring lab space to meet operational goals. Keane's appointment is expected to enhance Tevogen's strategic decision-making and further its mission in oncology, neurology, and virology therapeutics development.
Tevogen Bio Holdings Inc. has secured up to $50 million in financing to advance its ExacTcell platform and further clinical trials. The financing supports ongoing research and development efforts, including expanding clinical trials for TVGN 489 in oncology, neurology, and virology. The capital will also aid in starting new trials for virally induced cancers and multiple sclerosis. Dr. Ryan Saadi, Tevogen Bio's CEO, expressed gratitude for the support of existing shareholders, emphasizing the company's commitment to providing affordable T cell therapies for a wide range of patients.
Tevogen Bio announced its full-year 2023 financial results, highlighted its ExacTcell platform success, and upcoming operational objectives. The company aims to acquire a cell therapy manufacturing facility, expand clinical trials, and address Long COVID treatment. Tevogen Bio reported positive POC results for TVGN 489, showcasing safety and efficacy. The company is in discussions to secure manufacturing facilities, bolster research and development capabilities, and seek FDA approval for new clinical trials. Tevogen Bio is evaluating funding options to support growth plans, emphasizing favorable financing terms and equity control. Operating expenses for 2023 were $8.8 million, with significant liabilities converted to common stock.
Tevogen Bio CEO announced the elimination of $94.9 million in liabilities through the conversion of promissory notes into common stock. The company's total outstanding shares now stand at 165 million. Tevogen also introduced the Tevogen.ai initiative to leverage AI for drug discovery, development, and patient access. Key leadership appointments were highlighted, including Mittul Mehta as CIO and Tapan V. Shah as Head of Investor Relations and Corporate Development.
